Pinnacle Wealth Planning Services’s Viking Therapeutics VKTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$78.3K Sell
2,402
-31
-1% -$1.07K 0.01% 1017
2026
Q2
$94.9K Buy
2,433
+6
+0.2% +$194 0.01% 901
2026
Q1
$79K Buy
2,427
+201
+9% +$6.46K 0.01% 935
2025
Q4
$78.3K Buy
+2,226
New +$78.9K 0.01% 922
2024
Q4
– Sell
-6,507
Closed -$412K – 557
2024
Q3
$412K Sell
6,507
-284
-4% -$16.7K 0.06% 227
2024
Q2
$360K Sell
6,791
-838
-11% -$54.9K 0.05% 240
2024
Q1
$626K Sell
7,629
-8,177
-52% -$364K 0.09% 144
2023
Q4
$294K Hold
15,806
– – 0.05% 277
2023
Q3
$175K Hold
15,806
– – 0.03% 378
2023
Q2
$256K Sell
15,806
-10,063
-39% -$211K 0.04% 297
2023
Q1
$431K Sell
25,869
-1,078
-4% -$11.1K 0.07% 198
2022
Q4
$253K Hold
26,947
– – 0.05% 297
2022
Q3
$73K Hold
26,947
– – 0.01% 383
2022
Q2
$78K Buy
+26,947
New +$66.7K 0.01% 394

Other funds holding VKTX

Pinnacle Wealth Planning Services's VKTX Position: Q3 2026 in Review

Pinnacle Wealth Planning Services reduced its Viking Therapeutics (VKTX) stake by 1.3% in Q3 2026, selling an estimated $1.07K and leaving 2,402 shares worth $78.3K. The position accounts for 0.01% of the portfolio, ranked #1017.

Pinnacle Wealth Planning Services first reported a position in VKTX in Q2 2022 and has held it in 14 quarters since. The position peaked at $626K in Q1 2024. 444 funds tracked by Wall St. Rank hold VKTX as of Q3 2026.

  • Pinnacle Wealth Planning Services held 2,402 shares of Viking Therapeutics worth $78.3K as of Q3 2026.
  • Pinnacle Wealth Planning Services sold 31 Viking Therapeutics shares in Q3 2026, an estimated $1.07K.
  • Viking Therapeutics made up 0.01% of Pinnacle Wealth Planning Services's portfolio in Q3 2026, its #1017 holding.
  • Pinnacle Wealth Planning Services first reported a position in Viking Therapeutics in Q2 2022 and has held it in 14 quarters since.
  • Pinnacle Wealth Planning Services's Viking Therapeutics position peaked at $626K in Q1 2024.
  • 444 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2026.

Based on Pinnacle Wealth Planning Services's 13F filing for Q3 2026, filed 27 Oct 2026.